Pfizer/BioNTech's Covid-19 Vaccine in a Nationwide Mass Vaccination Setting in Israel

Pfizer/BioNTech's vaccine was effective against symptomatic (~92% at 7 days post dose 2) and asymptomatic infections (~90%). However, the study didn’t test the vaccine’s efficacy on variants, which were rare in Israel at the time of data extraction.  The New England Journal of Medicine

Other news